Cargando…
IDO Inhibitor and Gallic Acid Cross-Linked Small Molecule Drug Synergistic Treatment of Melanoma
In this study, we synthesized a molecule GA-1MT (GM) composed of indoleamine 2,3-dioxygenase (IDO) inhibitor (1-methyl-d-tryptophan, 1MT) called NLG8189 and gallic acid (GA) and verified its therapeutic effect on B16F10 melanoma cells and an orthotopic tumor-bearing mouse model. The synthesized mole...
Autores principales: | Liu, Hongmei, Gao, Huan, Chen, Cheng, Jia, Wenyu, Xu, Delong, Jiang, Guan |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Frontiers Media S.A.
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9303008/ https://www.ncbi.nlm.nih.gov/pubmed/35875081 http://dx.doi.org/10.3389/fonc.2022.904229 |
Ejemplares similares
-
Construction of immunotherapy-related prognostic gene signature and small molecule drug prediction for cutaneous melanoma
por: Xing, Jiahua, et al.
Publicado: (2022) -
The enhanced antitumour response of pimozide combined with the IDO inhibitor L-MT in melanoma
por: Jia, Huijie, et al.
Publicado: (2018) -
Small Molecule Inhibitor C188-9 Synergistically Enhances the Demethylated Activity of Low-Dose 5-Aza-2′-Deoxycytidine Against Pancreatic Cancer
por: Kong, Rui, et al.
Publicado: (2020) -
Updates in the Clinical Development of Epacadostat and Other Indoleamine 2,3-Dioxygenase 1 Inhibitors (IDO1) for Human Cancers
por: Komiya, Takefumi, et al.
Publicado: (2018) -
Thinking Small: Small Molecules as Potential Synergistic Adjuncts to Checkpoint Inhibition in Melanoma
por: Chacon, Alexander C., et al.
Publicado: (2021)